Compare Adaptive Biotechnologies Corp (ADPT) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Direxion Daily S&P 500 Bull 3X Shares trades at $267.48. Which is the better fit depends on your goals.
| ADPT | SPXL | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $22.37 | $288.04 |
52-Week Low | $10.24 | $170.20 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
SPXL, a leveraged ETF tracking the S&P 500, trades at $275.77, up 2.62% with strong bullish technical signals from moving averages. Recent sector rotation has pressured tech stocks, though broader market optimism persists. The fund's performance is tied to daily S&P 500 returns, with a dividend scheduled for June 2026.
Outlook remains tied to S&P 500 momentum, with potential for gains if earnings meet high expectations, but risks include volatility decay from daily rebalancing and market corrections. Investors should weigh the ETF's leverage against broader economic indicators and sector performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
